Literature DB >> 20308078

MDM2 promotes proteasomal degradation of p21Waf1 via a conformation change.

Hongxia Xu1, Zhuo Zhang, Mao Li, Ruiwen Zhang.   

Abstract

MDM2 plays a major role in cancer development and progression via both p53-dependent and -independent functions. One of its p53-independent functions is the induction of the ubiquitin-independent proteasomal degradation of p21(Waf1). The present study was designed to characterize the mechanism(s) by which MDM2 induces p21(Waf1) degradation. We first determined the regions of MDM2 required for p21(Waf1) degradation using pulldown assays and Western blotting and then examined the mechanisms using limited proteolysis and fluorescence resonance energy transfer assays. We found that the MDM2-p21(Waf1) interaction depended on the central domain of MDM2 and that nuclear localization of both proteins was necessary for p21(Waf1) degradation. Specifically, amino acids 226-250 of MDM2 were required for p21(Waf1) binding and degradation, and amino acids 251-260 were necessary for p21(Waf1) degradation. The latter region induced a conformation change in p21(Waf1), increasing its interaction with the C8 subunit of the proteasome, leading to its degradation. When MDM2 lacked either segment (aa 226-250 or aa 251-260), its capacity to promote p21(Waf1) degradation and cell cycle progression was significantly reduced. In summary, the present study elucidated a previously unknown mechanism by which MDM2 promotes the degradation of an intact protein (p21(Waf1)) through an ubiquitin-independent proteasomal degradation pathway. Because MDM2 also increases the degradation of other proteins in a ubiquitin-independent manner, this mechanism may underlie part of its tumorigenic properties.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20308078      PMCID: PMC2881766          DOI: 10.1074/jbc.M109.059568

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  44 in total

1.  A degradation signal located in the C-terminus of p21WAF1/CIP1 is a binding site for the C8 alpha-subunit of the 20S proteasome.

Authors:  R Touitou; J Richardson; S Bose; M Nakanishi; J Rivett; M J Allday
Journal:  EMBO J       Date:  2001-05-15       Impact factor: 11.598

2.  Coupled folding and binding with alpha-helix-forming molecular recognition elements.

Authors:  Christopher J Oldfield; Yugong Cheng; Marc S Cortese; Pedro Romero; Vladimir N Uversky; A Keith Dunker
Journal:  Biochemistry       Date:  2005-09-20       Impact factor: 3.162

Review 3.  p53-independent activities of MDM2 and their relevance to cancer therapy.

Authors:  Zhuo Zhang; Ruiwen Zhang
Journal:  Curr Cancer Drug Targets       Date:  2005-02       Impact factor: 3.428

Review 4.  MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy.

Authors:  Elizabeth Rayburn; Ruiwen Zhang; Jie He; Hui Wang
Journal:  Curr Cancer Drug Targets       Date:  2005-02       Impact factor: 3.428

5.  Opposing effects of Ras on p53: transcriptional activation of mdm2 and induction of p19ARF.

Authors:  S Ries; C Biederer; D Woods; O Shifman; S Shirasawa; T Sasazuki; M McMahon; M Oren; F McCormick
Journal:  Cell       Date:  2000-10-13       Impact factor: 41.582

6.  MDM2 promotes proteasome-dependent ubiquitin-independent degradation of retinoblastoma protein.

Authors:  Patima Sdek; Haoqiang Ying; Donny L F Chang; Wei Qiu; Hongwu Zheng; Robert Touitou; Martin J Allday; Zhi-Xiong Jim Xiao
Journal:  Mol Cell       Date:  2005-12-09       Impact factor: 17.970

7.  Growth inhibition by CDK-cyclin and PCNA binding domains of p21 occurs by distinct mechanisms and is regulated by ubiquitin-proteasome pathway.

Authors:  D Rousseau; D Cannella; J Boulaire; P Fitzgerald; A Fotedar; R Fotedar
Journal:  Oncogene       Date:  1999-07-29       Impact factor: 9.867

8.  Intrinsic disorder in cell-signaling and cancer-associated proteins.

Authors:  Lilia M Iakoucheva; Celeste J Brown; J David Lawson; Zoran Obradović; A Keith Dunker
Journal:  J Mol Biol       Date:  2002-10-25       Impact factor: 5.469

9.  Regulation of receptor fate by ubiquitination of activated beta 2-adrenergic receptor and beta-arrestin.

Authors:  S K Shenoy; P H McDonald; T A Kohout; R J Lefkowitz
Journal:  Science       Date:  2001-10-04       Impact factor: 47.728

10.  14-3-3Tau regulates ubiquitin-independent proteasomal degradation of p21, a novel mechanism of p21 downregulation in breast cancer.

Authors:  Bing Wang; Kang Liu; Hui-Yi Lin; Naresh Bellam; Shiyun Ling; Weei-Chin Lin
Journal:  Mol Cell Biol       Date:  2010-01-19       Impact factor: 4.272

View more
  19 in total

1.  CHIP protects against cardiac pressure overload through regulation of AMPK.

Authors:  Jonathan C Schisler; Carrie E Rubel; Chunlian Zhang; Pamela Lockyer; Douglas M Cyr; Cam Patterson
Journal:  J Clin Invest       Date:  2013-07-25       Impact factor: 14.808

Review 2.  Context-dependent resistance to proteolysis of intrinsically disordered proteins.

Authors:  Marcin J Suskiewicz; Joel L Sussman; Israel Silman; Yosef Shaul
Journal:  Protein Sci       Date:  2011-06-08       Impact factor: 6.725

3.  Mdm2 promotes Cdc25C protein degradation and delays cell cycle progression through the G2/M phase.

Authors:  L E Giono; L Resnick-Silverman; L A Carvajal; S St Clair; J J Manfredi
Journal:  Oncogene       Date:  2017-08-14       Impact factor: 9.867

4.  A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance.

Authors:  Dharminder Chauhan; Ze Tian; Benjamin Nicholson; K G Suresh Kumar; Bin Zhou; Ruben Carrasco; Jeffrey L McDermott; Craig A Leach; Mariaterresa Fulcinniti; Matthew P Kodrasov; Joseph Weinstock; William D Kingsbury; Teru Hideshima; Parantu K Shah; Stephane Minvielle; Mikael Altun; Benedikt M Kessler; Robert Orlowski; Paul Richardson; Nikhil Munshi; Kenneth C Anderson
Journal:  Cancer Cell       Date:  2012-09-11       Impact factor: 31.743

Review 5.  The 26S proteasome complex: an attractive target for cancer therapy.

Authors:  Sarah Frankland-Searby; Sukesh R Bhaumik
Journal:  Biochim Biophys Acta       Date:  2011-10-18

6.  Differential regulation of p21 (waf1) protein half-life by DNA damage and Nutlin-3 in p53 wild-type tumors and its therapeutic implications.

Authors:  Li-Ju Chang; Alan Eastman
Journal:  Cancer Biol Ther       Date:  2012-07-24       Impact factor: 4.742

7.  14-3-3Gamma inhibition of MDMX-mediated p21 turnover independent of p53.

Authors:  Jun-Ho Lee; Hua Lu
Journal:  J Biol Chem       Date:  2010-12-09       Impact factor: 5.157

8.  MDM2, MDMX, and p73 regulate cell-cycle progression in the absence of wild-type p53.

Authors:  Alyssa M Klein; Lynn Biderman; David Tong; Bita Alaghebandan; Sakina A Plumber; Helen S Mueller; Anne van Vlimmeren; Chen Katz; Carol Prives
Journal:  Proc Natl Acad Sci U S A       Date:  2021-11-02       Impact factor: 11.205

9.  Natural product ginsenoside 25-OCH3-PPD inhibits breast cancer growth and metastasis through down-regulating MDM2.

Authors:  Wei Wang; Xu Zhang; Jiang-Jiang Qin; Sukesh Voruganti; Subhasree Ashok Nag; Ming-Hai Wang; Hui Wang; Ruiwen Zhang
Journal:  PLoS One       Date:  2012-07-23       Impact factor: 3.240

Review 10.  Integration of DNA damage and repair with murine double-minute 2 (Mdm2) in tumorigenesis.

Authors:  Jason A Lehman; Lindsey D Mayo
Journal:  Int J Mol Sci       Date:  2012-12-03       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.